Arfolitixorin
Metastatic Colorectal Cancer (mCRC)
Key Facts
About Isofol Medical
Isofol Medical is a clinical-stage biotech company developing arfolitixorin, an optimized folate designed to potentiate standard 5-FU-based chemotherapy in metastatic colorectal cancer (mCRC). The company is currently conducting a Phase Ib/II study and is publicly traded on Nasdaq Stockholm. With a focus on a high-mortality cancer where current folate therapies are suboptimal, Isofol seeks to address a significant unmet medical need and improve standard-of-care outcomes.
View full company profileAbout Isofol Medical
Isofol Medical is a clinical-stage biotech company developing arfolitixorin, an optimized folate designed to potentiate standard 5-FU-based chemotherapy in metastatic colorectal cancer (mCRC). The company is currently conducting a Phase Ib/II study and is publicly traded on Nasdaq Stockholm. With a focus on a high-mortality cancer where current folate therapies are suboptimal, Isofol seeks to address a significant unmet medical need and improve standard-of-care outcomes.
View full company profileOther Metastatic Colorectal Cancer (mCRC) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCO-101 (CORIST Trial) | Scandion Oncology | Phase 2 |